Fragrance avoidance
No fragrance-linked caution surfaced in the current profile.
This ingredient does not currently read as a fragrance-linked driver in the published evidence and hazard profile.
EPA CPDat observed this chemical in 12 composition records across product categories including Personal care.
Concern score
The concern value is driven by the published classifications and regulatory status below — not by a single signal.
Concern score 45/100 (moderate) · high confidence.
Prevalence of MEDIUM-CHAIN TRIGLYCERIDES in our catalog (epa_cpdat).
Products
12
Brands
6
Context-specific fit derived from published classifications and the current ingredient evidence profile.
Fragrance avoidance
No fragrance-linked caution surfaced in the current profile.
This ingredient does not currently read as a fragrance-linked driver in the published evidence and hazard profile.
The published evidence profile currently shaping this ingredient record.
Primary documents currently linked to this ingredient record.
Structured claim signals pulled from linked ingredient research.
Published jurisdiction-level classifications and regulatory designations for this ingredient.
US
EPA
EPA CPDat observed this chemical in 12 composition records across product categories including Personal care.
US
FDA
Route: INTRAVENOUS; Dosage form: INJECTION, EMULSION; Potency: 1.1 %w/v
US
FDA
Route: ORAL; Dosage form: CAPSULE; Maximum daily exposure: 4771 mg
US
FDA
Route: ORAL; Dosage form: CAPSULE, LIQUID FILLED; Maximum daily exposure: 866 mg
US
FDA
Route: ORAL; Dosage form: POWDER, FOR SUSPENSION; Potency: 3390 mg/5ml
US
FDA
Route: ORAL; Dosage form: SOLUTION; Maximum daily exposure: 5566 mg
US
FDA
Route: ORAL; Dosage form: SUSPENSION; Maximum daily exposure: 10170 mg
US
FDA
Route: ORAL; Dosage form: TABLET; Maximum daily exposure: 2 mg
US
FDA
Route: ORAL; Dosage form: TABLET, EXTENDED RELEASE; Potency: 0.37 mg
US
FDA
Route: ORAL; Dosage form: TABLET, ORALLY DISINTEGRATING; Maximum daily exposure: 1 mg
US
FDA
Route: SUBCUTANEOUS; Dosage form: INJECTION, SUSPENSION, EXTENDED RELEASE; Maximum daily exposure: 990 mg
US
FDA
Route: SUBLINGUAL; Dosage form: POWDER; Maximum daily exposure: 2 mg
US
FDA
Route: SUBLINGUAL; Dosage form: SPRAY, METERED; Maximum daily exposure: 110 mg
US
FDA
Route: TOPICAL; Dosage form: AEROSOL, FOAM; Potency: 10.87 %w/w
US
FDA
Route: TOPICAL; Dosage form: CREAM; Maximum daily exposure: 570 mg
US
FDA
Route: TOPICAL; Dosage form: GEL; Maximum daily exposure: 12 mg
US
FDA
Route: TOPICAL; Dosage form: OINTMENT; Potency: 20 %w/w
US
FDA
Route: TOPICAL; Dosage form: SPRAY; Maximum daily exposure: 540 mg
US
FDA
Route: TRANSDERMAL; Dosage form: FILM, EXTENDED RELEASE; Potency: NA
US
FDA
FDA NDC lists this ingredient in 1 active drug products and 4 total products.